TriNetX and Regeneron announced a data partnership to link genomic and proteomic information for drug discovery and development. TriNetX will provide Regeneron exclusive, secure access to de-identified health data from roughly 300 million individuals, expanding the breadth of real-world data available for hypothesis generation and target validation. For Regeneron, the partnership helps connect biological layers—genomics and proteomics—into a single evidence stream intended to support compound design and clinical development. As data scale and multimodal datasets become central to biotech discovery platforms, the deal further increases competitive pressure on health-data ecosystems and data integration providers.